A scientist designing a new protein using computer software

Af­ter years of hype, the first AI-de­signed drugs fall short in the clin­ic

The first AI-de­signed drugs have end­ed with dis­ap­point­ment.

Over the last year-plus, the first hand­ful of mol­e­cules cre­at­ed by ar­ti­fi­cial in­tel­li­gence have failed tri­als or been de­pri­or­i­tized. The AI com­pa­nies be­hind these drugs brought them in­to the clin­ic full of fan­fare about a new age of drug dis­cov­ery — and have qui­et­ly shelved them af­ter learn­ing old lessons about how hard phar­ma­ceu­ti­cal R&D can be.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.